Summary

The global market for Drugs for Vulvovaginal Candidiasis was estimated to be worth US$ 841 million in 2024 and is forecast to a readjusted size of US$ 932 million by 2031 with a CAGR of 1.5% during the forecast period 2025-2031.
The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for at least 72 hours after the ingestion of a single 150-mg tablet.

Some women with recurrent candidal infections opt for treatment with over-the-counter (OTC) medications, which generally are highly effective for candidiasis. Preparations for intravaginal administration of butoconazole, clotrimazole, miconazole, and tioconazole are available OTC.
The main manufacturers of Drugs for Vulvovaginal Candidiasis are Bayer, J & J, Pfizer, Perrigo, Effik, etc. The top three manufacturers in the world occupy about 40% of the market share.

The Asia-Pacific region is the world"s largest market, with a market share of about 45%, followed by North America with nearly 20%
This report aims to provide a comprehensive presentation of the global market for Drugs for Vulvovaginal Candidiasis, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Drugs for Vulvovaginal Candidiasis by region & country, by Type, and by Application.

The Drugs for Vulvovaginal Candidiasis market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drugs for Vulvovaginal Candidiasis.

Market Segmentation
By Company
Bayer
Perrigo
J & J
Pfizer
Bristol-Myers Squibb
Effik
Teva
Sanofi
Cisen Pharmaceutical
Kingyork Group
Segment by Type
Cream
Pessary
Other
Segment by Application
Hospital & Clinic
Pharmacy
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Drugs for Vulvovaginal Candidiasis manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Drugs for Vulvovaginal Candidiasis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Drugs for Vulvovaginal Candidiasis in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

ページTOPに戻る

Table of Contents

1 Market Overview
1.1 Drugs for Vulvovaginal Candidiasis Product Introduction
1.2 Global Drugs for Vulvovaginal Candidiasis Market Size Forecast
1.2.1 Global Drugs for Vulvovaginal Candidiasis Sales Value (2020-2031)
1.2.2 Global Drugs for Vulvovaginal Candidiasis Sales Volume (2020-2031)
1.2.3 Global Drugs for Vulvovaginal Candidiasis Sales Price (2020-2031)
1.3 Drugs for Vulvovaginal Candidiasis Market Trends & Drivers
1.3.1 Drugs for Vulvovaginal Candidiasis Industry Trends
1.3.2 Drugs for Vulvovaginal Candidiasis Market Drivers & Opportunity
1.3.3 Drugs for Vulvovaginal Candidiasis Market Challenges
1.3.4 Drugs for Vulvovaginal Candidiasis Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Drugs for Vulvovaginal Candidiasis Players Revenue Ranking (2024)
2.2 Global Drugs for Vulvovaginal Candidiasis Revenue by Company (2020-2025)
2.3 Global Drugs for Vulvovaginal Candidiasis Players Sales Volume Ranking (2024)
2.4 Global Drugs for Vulvovaginal Candidiasis Sales Volume by Company Players (2020-2025)
2.5 Global Drugs for Vulvovaginal Candidiasis Average Price by Company (2020-2025)
2.6 Key Manufacturers Drugs for Vulvovaginal Candidiasis Manufacturing Base and Headquarters
2.7 Key Manufacturers Drugs for Vulvovaginal Candidiasis Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Drugs for Vulvovaginal Candidiasis
2.9 Drugs for Vulvovaginal Candidiasis Market Competitive Analysis
2.9.1 Drugs for Vulvovaginal Candidiasis Market Concentration Rate (2020-2025)
2.9.2 Global 5 and 10 Largest Manufacturers by Drugs for Vulvovaginal Candidiasis Revenue in 2024
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Vulvovaginal Candidiasis as of 2024)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Cream
3.1.2 Pessary
3.1.3 Other
3.2 Global Drugs for Vulvovaginal Candidiasis Sales Value by Type
3.2.1 Global Drugs for Vulvovaginal Candidiasis Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Drugs for Vulvovaginal Candidiasis Sales Value, by Type (2020-2031)
3.2.3 Global Drugs for Vulvovaginal Candidiasis Sales Value, by Type (%) (2020-2031)
3.3 Global Drugs for Vulvovaginal Candidiasis Sales Volume by Type
3.3.1 Global Drugs for Vulvovaginal Candidiasis Sales Volume by Type (2020 VS 2024 VS 2031)
3.3.2 Global Drugs for Vulvovaginal Candidiasis Sales Volume, by Type (2020-2031)
3.3.3 Global Drugs for Vulvovaginal Candidiasis Sales Volume, by Type (%) (2020-2031)
3.4 Global Drugs for Vulvovaginal Candidiasis Average Price by Type (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital & Clinic
4.1.2 Pharmacy
4.2 Global Drugs for Vulvovaginal Candidiasis Sales Value by Application
4.2.1 Global Drugs for Vulvovaginal Candidiasis Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global Drugs for Vulvovaginal Candidiasis Sales Value, by Application (2020-2031)
4.2.3 Global Drugs for Vulvovaginal Candidiasis Sales Value, by Application (%) (2020-2031)
4.3 Global Drugs for Vulvovaginal Candidiasis Sales Volume by Application
4.3.1 Global Drugs for Vulvovaginal Candidiasis Sales Volume by Application (2020 VS 2024 VS 2031)
4.3.2 Global Drugs for Vulvovaginal Candidiasis Sales Volume, by Application (2020-2031)
4.3.3 Global Drugs for Vulvovaginal Candidiasis Sales Volume, by Application (%) (2020-2031)
4.4 Global Drugs for Vulvovaginal Candidiasis Average Price by Application (2020-2031)
5 Segmentation by Region
5.1 Global Drugs for Vulvovaginal Candidiasis Sales Value by Region
5.1.1 Global Drugs for Vulvovaginal Candidiasis Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Drugs for Vulvovaginal Candidiasis Sales Value by Region (2020-2025)
5.1.3 Global Drugs for Vulvovaginal Candidiasis Sales Value by Region (2026-2031)
5.1.4 Global Drugs for Vulvovaginal Candidiasis Sales Value by Region (%), (2020-2031)
5.2 Global Drugs for Vulvovaginal Candidiasis Sales Volume by Region
5.2.1 Global Drugs for Vulvovaginal Candidiasis Sales Volume by Region: 2020 VS 2024 VS 2031
5.2.2 Global Drugs for Vulvovaginal Candidiasis Sales Volume by Region (2020-2025)
5.2.3 Global Drugs for Vulvovaginal Candidiasis Sales Volume by Region (2026-2031)
5.2.4 Global Drugs for Vulvovaginal Candidiasis Sales Volume by Region (%), (2020-2031)
5.3 Global Drugs for Vulvovaginal Candidiasis Average Price by Region (2020-2031)
5.4 North America
5.4.1 North America Drugs for Vulvovaginal Candidiasis Sales Value, 2020-2031
5.4.2 North America Drugs for Vulvovaginal Candidiasis Sales Value by Country (%), 2024 VS 2031
5.5 Europe
5.5.1 Europe Drugs for Vulvovaginal Candidiasis Sales Value, 2020-2031
5.5.2 Europe Drugs for Vulvovaginal Candidiasis Sales Value by Country (%), 2024 VS 2031
5.6 Asia Pacific
5.6.1 Asia Pacific Drugs for Vulvovaginal Candidiasis Sales Value, 2020-2031
5.6.2 Asia Pacific Drugs for Vulvovaginal Candidiasis Sales Value by Region (%), 2024 VS 2031
5.7 South America
5.7.1 South America Drugs for Vulvovaginal Candidiasis Sales Value, 2020-2031
5.7.2 South America Drugs for Vulvovaginal Candidiasis Sales Value by Country (%), 2024 VS 2031
5.8 Middle East & Africa
5.8.1 Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales Value, 2020-2031
5.8.2 Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Drugs for Vulvovaginal Candidiasis Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Drugs for Vulvovaginal Candidiasis Sales Value
6.2.1 Key Countries/Regions Drugs for Vulvovaginal Candidiasis Sales Value, 2020-2031
6.2.2 Key Countries/Regions Drugs for Vulvovaginal Candidiasis Sales Volume, 2020-2031
6.3 United States
6.3.1 United States Drugs for Vulvovaginal Candidiasis Sales Value, 2020-2031
6.3.2 United States Drugs for Vulvovaginal Candidiasis Sales Value by Type (%), 2024 VS 2031
6.3.3 United States Drugs for Vulvovaginal Candidiasis Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe Drugs for Vulvovaginal Candidiasis Sales Value, 2020-2031
6.4.2 Europe Drugs for Vulvovaginal Candidiasis Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe Drugs for Vulvovaginal Candidiasis Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China Drugs for Vulvovaginal Candidiasis Sales Value, 2020-2031
6.5.2 China Drugs for Vulvovaginal Candidiasis Sales Value by Type (%), 2024 VS 2031
6.5.3 China Drugs for Vulvovaginal Candidiasis Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan Drugs for Vulvovaginal Candidiasis Sales Value, 2020-2031
6.6.2 Japan Drugs for Vulvovaginal Candidiasis Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan Drugs for Vulvovaginal Candidiasis Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Drugs for Vulvovaginal Candidiasis Sales Value, 2020-2031
6.7.2 South Korea Drugs for Vulvovaginal Candidiasis Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea Drugs for Vulvovaginal Candidiasis Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Drugs for Vulvovaginal Candidiasis Sales Value, 2020-2031
6.8.2 Southeast Asia Drugs for Vulvovaginal Candidiasis Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia Drugs for Vulvovaginal Candidiasis Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India Drugs for Vulvovaginal Candidiasis Sales Value, 2020-2031
6.9.2 India Drugs for Vulvovaginal Candidiasis Sales Value by Type (%), 2024 VS 2031
6.9.3 India Drugs for Vulvovaginal Candidiasis Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 Bayer
7.1.1 Bayer Company Information
7.1.2 Bayer Introduction and Business Overview
7.1.3 Bayer Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2020-2025)
7.1.4 Bayer Drugs for Vulvovaginal Candidiasis Product Offerings
7.1.5 Bayer Recent Development
7.2 Perrigo
7.2.1 Perrigo Company Information
7.2.2 Perrigo Introduction and Business Overview
7.2.3 Perrigo Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2020-2025)
7.2.4 Perrigo Drugs for Vulvovaginal Candidiasis Product Offerings
7.2.5 Perrigo Recent Development
7.3 J & J
7.3.1 J & J Company Information
7.3.2 J & J Introduction and Business Overview
7.3.3 J & J Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2020-2025)
7.3.4 J & J Drugs for Vulvovaginal Candidiasis Product Offerings
7.3.5 J & J Recent Development
7.4 Pfizer
7.4.1 Pfizer Company Information
7.4.2 Pfizer Introduction and Business Overview
7.4.3 Pfizer Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2020-2025)
7.4.4 Pfizer Drugs for Vulvovaginal Candidiasis Product Offerings
7.4.5 Pfizer Recent Development
7.5 Bristol-Myers Squibb
7.5.1 Bristol-Myers Squibb Company Information
7.5.2 Bristol-Myers Squibb Introduction and Business Overview
7.5.3 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2020-2025)
7.5.4 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Product Offerings
7.5.5 Bristol-Myers Squibb Recent Development
7.6 Effik
7.6.1 Effik Company Information
7.6.2 Effik Introduction and Business Overview
7.6.3 Effik Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2020-2025)
7.6.4 Effik Drugs for Vulvovaginal Candidiasis Product Offerings
7.6.5 Effik Recent Development
7.7 Teva
7.7.1 Teva Company Information
7.7.2 Teva Introduction and Business Overview
7.7.3 Teva Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2020-2025)
7.7.4 Teva Drugs for Vulvovaginal Candidiasis Product Offerings
7.7.5 Teva Recent Development
7.8 Sanofi
7.8.1 Sanofi Company Information
7.8.2 Sanofi Introduction and Business Overview
7.8.3 Sanofi Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2020-2025)
7.8.4 Sanofi Drugs for Vulvovaginal Candidiasis Product Offerings
7.8.5 Sanofi Recent Development
7.9 Cisen Pharmaceutical
7.9.1 Cisen Pharmaceutical Company Information
7.9.2 Cisen Pharmaceutical Introduction and Business Overview
7.9.3 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2020-2025)
7.9.4 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Product Offerings
7.9.5 Cisen Pharmaceutical Recent Development
7.10 Kingyork Group
7.10.1 Kingyork Group Company Information
7.10.2 Kingyork Group Introduction and Business Overview
7.10.3 Kingyork Group Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin (2020-2025)
7.10.4 Kingyork Group Drugs for Vulvovaginal Candidiasis Product Offerings
7.10.5 Kingyork Group Recent Development
8 Industry Chain Analysis
8.1 Drugs for Vulvovaginal Candidiasis Industrial Chain
8.2 Drugs for Vulvovaginal Candidiasis Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Drugs for Vulvovaginal Candidiasis Sales Model
8.5.2 Sales Channel
8.5.3 Drugs for Vulvovaginal Candidiasis Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer